Spotlight on montelukast in asthma in children 2 to 14 years of age

American Journal of Respiratory Medicine

Volumn 1, Issue 3, 2002, Pages 225-228

  Muijsers, Richard B R ^a   Noble, Stuart ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DIGOXIN; FEXOFENADINE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; NEDOCROMIL; NITRIC OXIDE; ORAL CONTRACEPTIVE AGENT; PEPTIDOLEUKOTRIENE; PHENOBARBITAL; PLACEBO; PREDNISOLONE; PREDNISONE; TERFENADINE; THEOPHYLLINE; WARFARIN;

ABDOMINAL PAIN; ADOLESCENT; ARTICLE; ASTHMA; BRONCHOSPASM; CHILD; CHILDHOOD DISEASE; CLINICAL STUDY; CLINICAL TRIAL; COUGHING; DATA ANALYSIS; DIARRHEA; DISEASE EXACERBATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PREFERENCE; DRUG TOLERABILITY; DRUG USE; EXERCISE; FEVER; FORCED EXPIRATORY VOLUME; HUMAN; INFLUENZA; LUNG FUNCTION; MEDICAL DECISION MAKING; OUTCOMES RESEARCH; PARENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHARYNGITIS; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0042422329     PISSN: 11756365     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256612     Document Type: Article

References (38)

1. Sterk PJ. Rationale for leukotriene receptor antagonists as controller therapy for asthma. Eur Respir Rev 1999 Jun; 9 (Rev. 65): 7-12
2. Holgate ST, Sampson AP. Antileukotriene therapy: future directions. Am J Respir Crit Care Med 2000; 161: S147-53
3. Leff AR. Role of leukotrienes in bronchial hyperresponsiveness and cellular responses in airways. Am J Respir Crit Care Med 2000; 161: S125-32
4. Drazen JM. Leukotrienes as mediators of airway obstruction. Am J Respir Crit Care Med 1998; 158: S193-200
5. Wenzel SE. Inflammation, leukotrienes and the pathogenesis of the late asthmatic response. Clin Exp Allergy 1999; 29: 1-3
6. Rachelefsky G. Childhood asthma and allergic rhinitis: the role of leukotrienes. J Pediatr 1997; 131 (3): 348-55
7. Devillier P, Baccard N, Advenier C. Leukotrienes, leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma: an update. Part II: clinical studies with leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma. Pharmacol Res 1999; 40 (1): 15-29
8. Devillier P, Baccard N, Advenier C. Leukotrienes, leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma: an update. Part I: synthesis, receptors and role of leukotrienes in asthma. Pharmacol Res 1999; 40 (1): 3-13
9. Bisgaard H. Pathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor antagonists in asthma. Allergy 2001 May; 56 Suppl. 66 7-11
10. 4 receptor antagonist [published erratum appears in Can J Physiol Pharmacol 1995 Jun;73(6):747]. Can J Physiol Pharmacol 1995; 73: 191-201
11. 1 receptor. Nature 1999; 399: 789-93
12. Bisgaard H, Nielsen KG. Bronchoprotection with a leukotriene receptor antagonist in asthmatic preschool children. Am J Respir Crit Care Med 2000 Jul; 162 (1): 187-90
13. Bisgaard H, Loland L, Oj JA. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am J Respir Crit Care Med 1999 Oct; 160 (4): 1227-31
14. Bratton DL, Lanz MJ, Miyazawa N, et al. Exhaled nitric oxide before and after montelukast sodium therapy in school-age children with chronic asthma: a preliminary study. Pediatr Pulmonol 1999 Dee; 28 (6): 402-7
15. Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001 Sep; 108 (3): e48
16. Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA 1998 Apr 15; 279 (15): 1181-6
17. Simons FE, Villa JR, Lee BW, et al. Montelukast added to budesonide in children with persistent asthma: A randomized, double-blind, crossover study. J Pediatr 2001 May; 138 (5): 694-8
18. Volovitz B, Tabachnik E, Nussinovitch M, et al. Montelukast, a leukotriene receptor antagonist, reduces the concentration of leukotrienes in the respiratory tract of children with persistent asthma. J Allergy Clin Immunol 1999 Dec; 104 (6): 1162-7
19. Merck and Co. Inc. Singulair (montelukast) prescribing information. Rahway (NJ): Merck and Co. Inc., 2001
20. Knorr B, Larson P, Nguyen HH, et al. Montelukast dose selection in 6- to 14-year-olds: comparison of single-dose pharmacokinetics in children and adults. J Clin Pharmacol 1999 Aug; 39 (8): 786-93
21. Knorr B, Nguyen HH, Kearns GL, et al. Montelukast dose selection in children ages 2 to 5 years: comparison of population pharmacokinetics between children and adults. J Clin Pharmacol 2001 Jun; 41: 612-9
22. Balani SK, Xu X, Pratha V, et al. Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene, receptor antagonist, in human plasma and bile. Drug Metab Dispos 1997; 25: 1282-7
23. 4receptor antagonist, in humans. Drug Metab Dispos 1997; 25: 1022-31
24. Knorr B, Holland S, Rogers JD, et al. Montelukast adult (10-mg film-coated tablet) and pediatric (5-mg chewable tablet) dose selections. J Allergy Clin Immunol 2000 Sep; 106 (3 Suppl.): S171-8
25. Malmstrom K, Schwartz J, Reiss TF, et al. Effect of montelukast on single-dose theophylline pharmacokinetics. Am J Ther 1998; 5: 189-95
26. Van Hecken A, Depre M, Verbesselt R, et al. Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol 1999; 39 (5): 495-500
27. 1 receptor antagonist, on digoxin pharmacokinetics in healthy volunteers. J Clin Pharmacol 1999; 39 (9): 941-4
28. Holland S, Gertz B, DeSmet M, et al. Montelukast (MON) has no effect on terfenadine (T) pharmacokinetics (PK) or QTc [abstract PIII-99]. Clin Pharmacol Ther 1998; 63: 232
29. 4 receptor antagonist, montelukast (M), on ethinyl estradiol (EE) and norethindrone (NET) serum concentrations [abstract]. 98th Annual Meeting American Society for Clinical Pharmacology and Therapeutics; 1997; San Diego, 162
30. Holland S, Shahane A, Rogers JD, et al. Metabolism of montelukast is increased by multiple doses of phenobarbital [abstract PIII-99]. Clin Pharmacol Ther 1998; 63: 231
31. Williams B, Noonan G, Reiss TF, et al. Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older. Clin Exp Allergy 2001 Jun; 31 (6): 845-54
32. Volovitz B, Dueñas-Meza E, Chmielewska-Szewczyk DA, et al. Comparison of oral montelukast and inhaled cromolyn with respect to preference, satisfaction, and adherence: a multicenter, randomized, open-label, crossover study in children with mild to moderate persistent asthma. Curr Ther Res Clin Exp 2000; 61 (7): 490-506
33. Kemp JP, Dockhorn RJ, Shapiro GG, et al. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J Pediatr 1998; 133: 424-8
34. Capristo AF, del Giudice MM, Maiello N, et al. Montelukast for the treatment of exercise induced asthma in children, mid term study [abstract P362]. European Respiratory Society annual congress; 1999 Oct 9-13; Madrid
35. Becker A, Kumar R, Stewart L, et al. Chronobiology of exercise-induced bronchoconstriction in pediatric asthma: response to montelukast [abstract]. Am J Respir Crit Care Med 2000 Mar; 161 Suppl. Pt 2: 194
36. Storms W, Michele TM, Knorr B, et al. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged >6 years. Clin Exp Allergy 2001 Jan; 31 (1): 77-87
37. Merck Sharp & Dohme Limited. Singulair (Montelukast) prescribing information 4mg. Hoddesdon: Merck Sharp & Dohme, 2001
38. Merck Sharp & Dohme Limited. Singulair (Montelukast) prescribing information 10mg and 5mg. Hoddesdon: Merck Sharp & Dohme, 2001